DOJ’s Granston Memo and Recent Government-Requested Dismissal of False Claims Act Case Have Significant Implications for FDA-Regulated Entities

For more than twenty years, qui tam relators have played a significant role in setting the agenda for enforcement of the Federal Food, Drug, and Cosmetic Act through whistleblower lawsuits alleging that violations of the FDCA caused the federal government  to pay for drugs that it should not have paid for, and would not have paid for had it known of the violations.